Payment overview · 2025
General Payments
$363.59
22 reported records · 8 companies
Healthcare provider profile · identity verified
Ali Rene Mitchell, DO
Allopathic & Osteopathic Physicians|Family Medicine · ARKADELPHIA, AR · NPI 1295398865
Verified facts
What the public records show
CMS Open Payments records show Ali Rene Mitchell, DO received $363.59 in general payments during 2025 across 22 reported records.
Dexcom, Inc. accounted for 40.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $147.96 | 40.7% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $72.15 | 19.8% | 4 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $38.88 | 10.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.40 | 8.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.74 | 7.9% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $16.18 | 4.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.28 | 3.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.00 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $347.60 | 21 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $147.96 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $51.69 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.40 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.74 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 297 | 97 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 253 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 221 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 209 | 54 |
| Gabapentin | Gabapentin | 205 | 57 |
| Lisinopril | Lisinopril | 185 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 52 |
| Losartan Potassium | Losartan Potassium | 146 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 135 | 29 |
| Potassium Chloride | Potassium Chloride | 128 | 42 |
| Alprazolam | Alprazolam | 126 | 31 |
| Prednisone | Prednisone | 120 | 99 |
| Omeprazole | Omeprazole | 114 | 36 |
| Furosemide | Furosemide | 111 | 49 |
| Tizanidine Hcl | Tizanidine Hcl | 104 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 23 |
| Metformin Hcl | Metformin Hcl | 88 | 28 |
| Jardiance | Empagliflozin | 74 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 33 |
| Meloxicam | Meloxicam | 67 | 20 |
| Celecoxib | Celecoxib | 66 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 64 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 24 |
| Famotidine | Famotidine | 62 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 27 |
| Eliquis | Apixaban | 61 | 13 |
| Azithromycin | Azithromycin | 57 | 54 |
| Tramadol Hcl | Tramadol Hcl | 57 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 56 | 17 |
| Ozempic | Semaglutide | 55 | 12 |
| Mounjaro | Tirzepatide | 54 | 14 |
| Allopurinol | Allopurinol | 53 | 15 |
| Donepezil Hcl | Donepezil Hcl | 52 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 52 | 17 |
| Pregabalin | Pregabalin | 51 | 14 |
| Clonazepam | Clonazepam | 47 | 14 |
| Methocarbamol | Methocarbamol | 46 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 12 |
| Lorazepam | Lorazepam | 45 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Bumetanide | Bumetanide | 44 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 11 |
| Bupropion Xl | Bupropion Hcl | 43 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 41 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 12 |
| Sertraline Hcl | Sertraline Hcl | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 13 |
| Atenolol | Atenolol | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 14 |
| Valsartan | Valsartan | 34 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | suppressed |
| Colchicine | Colchicine | 31 | suppressed |
| Nystatin | Nystatin | 30 | 14 |
| Carvedilol | Carvedilol | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | 17 |
| Fluconazole | Fluconazole | 27 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 20 |
| Glipizide | Glipizide | 26 | suppressed |
| Simvastatin | Simvastatin | 26 | 11 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 19 |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 16 |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 18 |
| Trulicity | Dulaglutide | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Cefdinir | Cefdinir | 18 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | 11 |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $363.59 · 22 records | Dexcom, Inc. | BREZTRI, CAPLYTA, CAPVAXIVE, Dexcom G6 Transmitter, FARXIGA, GARDASIL 9, JARDIANCE, UBRELVY, XYOSTED | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error